{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:23:50Z","timestamp":1775665430221,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: National guidelines recommend adjuvant chemotherapy (AC) following resection for all stages of pancreatic cancer (PDAC), but the benefit of AC in Stage IA disease remains unclear. The objective of this study was to identify a subgroup of patients with Stage IA PDAC that could possibly forego AC. Study Design: The National Cancer Database (NCDB) was queried to identify all patients with Stage IA PDAC diagnosed from 2010 to 2021. Patients who received AC were compared to those who did not. Multivariable analysis was conducted to identify risk factors associated with overall survival (OS). Results: There were 1421 patients eligible for analysis. On multivariable analysis, we found nine factors associated with worse overall OS: advanced age (p = 0.0414), lower median income (p = 0.0148), Medicare (p = 0.0180), higher-grade tumor histology (p = 0.0182), LVI (p = 0.0028), positive surgical margins (p = 0.0027), examination of fewer than 12 lymph nodes (p = 0.0395), and a length of stay greater than 7 days (p &lt; 0.0001). OS was negatively correlated with an increased number of risk factors. Improved OS was observed following AC in patients with three (\u2206OS = +54 months; p = 0.0016) or four or more risk factors (\u2206OS = +11.4 months; p = 0.0250). However, patients with fewer than three risk factors did not experience improvement in OS following AC. Conclusions: AC does not appear to benefit Stage IA PDAC patients with fewer than three risk factors indicating that it may be safe to omit AC in these individuals.<\/jats:p>","DOI":"10.3390\/cancers18081195","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:26:39Z","timestamp":1775661999000},"page":"1195","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do All Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0340-1312","authenticated-orcid":false,"suffix":"III","given":"John M.","family":"Lyons","sequence":"first","affiliation":[{"name":"Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"},{"name":"Our Lady of the Lake Cancer Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7842-1225","authenticated-orcid":false,"given":"Mei-Chin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Program of Epidemiology and Population Health, School of Public Health, LSUHSC, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Avanzino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"},{"name":"Our Lady of the Lake Cancer Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5007","authenticated-orcid":false,"given":"Mohammad","family":"Al Efishat","sequence":"additional","affiliation":[{"name":"Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"},{"name":"Our Lady of the Lake Cancer Center, Baton Rouge, LA 70808, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4837-5218","authenticated-orcid":false,"given":"Quyen","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA"},{"name":"Department of Surgery, Howard University, Washington, DC 20059, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_3","unstructured":"Tempero, M.A., Malafa, M.P., Al-Hawary, M., Asbun, H., Behrman, S., Benson, A.B., Cardin, D.B., Cha, C., Chiorean, E.G., and Chung, V. (2020). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, National Comprehensive Cancer Network. Version 1.2020."},{"key":"ref_4","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jnci\/djaa004","article-title":"Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis","volume":"112","author":"Blackford","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Canadian Cancer Trials Group and the Unicancer-GI\u2013PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"APACT Investigators. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.hpb.2017.03.002","article-title":"Does adjuvant therapy improve overall survival for stage IA\/B pancreatic adenocarcinoma?","volume":"19","author":"Ostapoff","year":"2017","journal-title":"HPB"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1245\/s10434-022-11580-7","article-title":"Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma?","volume":"29","author":"Turner","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pan.2021.01.024","article-title":"Evaluation of the significance of adjuvant chemotherapy in patients with stage IA pancreatic ductal adenocarcinoma","volume":"21","author":"Izumo","year":"2021","journal-title":"Pancreatology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Xu, G., Chen, M., Wei, Q., Zhou, T., Chen, Z., Shen, M., and Wang, P. (2020). Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit from Chemotherapy: A Propensity Score Matching Study. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01018"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cncr.31787","article-title":"Role of adjuvant therapy in resected stage IA subcentimeter (T1a\/T1b) pancreatic cancer","volume":"125","author":"Shaib","year":"2019","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","article-title":"FOLFIRINOX for locally advanced and metastatic pancreatic cancer: Single institution retrospective review of efficacy and toxicity","volume":"30","author":"Gunturu","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_18","first-page":"413","article-title":"Natural and Chemotherapy-Induced Clonal Evolution of Tumors","volume":"82","author":"Ibragimova","year":"2017","journal-title":"Biochemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jso.27871","article-title":"Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma","volume":"131","author":"Muaddi","year":"2025","journal-title":"J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pan.2015.01.013","article-title":"Early onset pancreatic cancer: Risk factors, presentation and outcome","volume":"15","author":"Piciucchi","year":"2015","journal-title":"Pancreatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MPA.0b013e31825f3af4","article-title":"Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: A population-based analysis","volume":"42","author":"Amin","year":"2013","journal-title":"Pancreas"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jnci\/djaa048","article-title":"Health Insurance Coverage Disruptions and Cancer Care and Outcomes: Systematic Review of Published Research","volume":"112","author":"Yabroff","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","first-page":"542","article-title":"Health insurance status and cancer stage at diagnosis and survival in the United States","volume":"72","author":"Zhao","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lyons, J.M., Danos, D.M., Maniscalco, L.S., Yi, Y., Moaven, O., Wu, X., and Chu, Q. (2025). Medicaid Expansion Increases Treatment for Patients with Colon Cancer. Cancers, 17.","DOI":"10.3390\/cancers17020207"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.33265","article-title":"Positive impact of the Patient Protection and Affordable Care Act Medicaid expansion on Louisiana women with breast cancer","volume":"127","author":"Chu","year":"2021","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Doria, C., De Deyne, P., Dolan, S., Chung, J., Yatcilla, K., Zarifian, L., Remstein, R., and Schwartz, E. (2021). Municipality and Adjusted Gross Income Influence Outcome of Patients Diagnosed with Pancreatic Cancer in a Newly Developed Cancer Center in Mercer County New Jersey, USA, a Single Center Study. Cancers, 13.","DOI":"10.3390\/cancers13071498"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.hpb.2023.12.010","article-title":"Socioeconomic variables in the national cancer database: Utilization and impact of income and education in survival models for patients with resected pancreas cancer","volume":"26","author":"Luo","year":"2024","journal-title":"HPB"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lora, D.R., Mercedes, S.H., Post, Z., and Blogowski, W. (2025). Racial and socioeconomic disparities in surgical management and outcomes in pancreatic adenocarcinoma: A single-center experience in the last 13 years. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14588-w"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1097\/SLA.0000000000003706","article-title":"The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis","volume":"274","author":"Powers","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.surg.2024.07.047","article-title":"Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk","volume":"176","author":"Zou","year":"2024","journal-title":"Surgery"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.32604\/or.2023.028905","article-title":"Progress on diagnostic and prognostic markers of pancreatic cancer","volume":"31","author":"Yang","year":"2023","journal-title":"Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SLA.0000000000005977","article-title":"Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection","volume":"279","author":"Groot","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.23.02313","article-title":"Verona IPMN Consortium. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results from an International Multicenter Study","volume":"42","author":"Habib","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1195\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:39:44Z","timestamp":1775662784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081195"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081195","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]}}}